Friday, July 10, 2020

WEEK IN REVIEW – A tale of 2 pharma companies, casino earnings perk up

Most businesspeople in Delaware know little about Incyte. The pharmaceutical development company, based in DuPont research space at the Experimental Station has quietly built a portfolio of promising drugs while posting big losses. Earlier in the...

Incyte posts loss as stock price stays around 52-week high

Drug developer Incyte Corp. is reporting revenue from a new product on the market, although the company's loss widened in the first quarter, due to higher research and other expenses as its pharmaceuticals moved...

AstraZeneca $1.26 paying billion for developer of gout drug

  AstraZeneca headquarters in London. AstraZeneca is betting on the success of a promising drug used to treat gout in  its merger deal for Ardea Biosciences, Inc. AstraZeneca will acquire Ardea, a San Diego-based biotechnology company...

AstraZeneca, Bristol-Myers Squibb drug wins OK from European panel

AstraZeneca and Bristol-Myers Squibb Company reported a committee for a European Union agency has recommended the approval of FORXIGA tablets for the treatment of type 2 diabetes. The drug is used in additon to diet...

Biotech venture pairing researchers, companies under way

The Delaware Biotechnology Institute and the Delaware Economic Development Office announced eight research projects through the recently launched Delaware Bioscience Center for Advanced Technology (Bioscience CAT). CAT grants link researchers from Delaware academic and...

iBio antibody shows promise

Newark-based IBIO announced that its iBioLaunch plant-based technology for the production of a copy of palivizumab, an antibody that fights a condition that strikes infants. Palivizumab is used to cut hospitalizations, but its high cost...